All In Biotech

Investigational drug · Phase 3

HS-20093

Also called: Ris-Rez, Risvutatug rezetecan, GSK5764227

Not approved by FDA. In 16 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Neoplasms, Lung, Sarcoma, Osteosarcoma.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

16

14 still active

All registered trials

27

Any phase or sponsor naming "HS-20093"

First trial start

2023

Jun 8, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "HS-20093", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Neoplasms, Lung
  • Sarcoma
  • Osteosarcoma
  • Non-Small Cell Lung Cancer
  • Gastrointestinal Neoplasms
  • Head and Neck Squamous Cell Carcinoma
  • Esophageal Squamous Cell Carcinoma (ESCC)
  • Prostate Cancer
  • Lung Neoplasm
  • Advanced Solid Tumor

Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Prostate cancer · Stomach and esophageal cancer · Head and neck cancer · Sarcoma · Oncology · Kidney and urology · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "HS-20093" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 5 on PubMed

Also in development for Neoplasms, Lung

  • ESG401Phase 33 trials

    Qilu Pharmaceutical Co., Ltd. · Metastatic Breast Cancer, Triple-Negative Breast Cancer (TNBC), Neoplasms, Breast

  • JDQ443OpnurasibPhase 23 trials

    Novartis · Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation, Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation

  • TNO155Phase 22 trials

    Novartis · Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation, KRAS G12C Mutant Solid Tumors

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.